PDCD1 and hepatocellular carcinoma: Its combination with anti-PD-1 (nivolumab, BMS) in immunotherapy-naive patients with advanced/metastatic solid tumors (PDAC and HCC) was associated with 4/15 responses in HCC and 1/15 response in PDAC patients.